BRPI0517416A - inibidores de pi3 quinase gama para o tratamento de anemia - Google Patents

inibidores de pi3 quinase gama para o tratamento de anemia

Info

Publication number
BRPI0517416A
BRPI0517416A BRPI0517416-3A BRPI0517416A BRPI0517416A BR PI0517416 A BRPI0517416 A BR PI0517416A BR PI0517416 A BRPI0517416 A BR PI0517416A BR PI0517416 A BRPI0517416 A BR PI0517416A
Authority
BR
Brazil
Prior art keywords
anemia
treatment
gamma
kinase inhibitors
selective
Prior art date
Application number
BRPI0517416-3A
Other languages
English (en)
Inventor
Reinhard Wetzker
Angelika Mueller
Christian Rommel
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of BRPI0517416A publication Critical patent/BRPI0517416A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INIBIDORES DE PI3 QUINASE GAMA PARA O TRATAMENTO DE ANEMIA. A presente invenção refere-se ao uso de inibidores de PI3 Quinase gama seletivos para a produção de medicamento para o tratamento de distúrbios relacionados com deficiência de eritrócitos. Especificamente, a presente invenção refere-se ao uso de inibidores de PI3 Quinase gama seletivos, por exemplo, derivados benzênicos fundidos com azolidinona-vinila substituidas para o tratamento de anemia, incluindo anemia hemolitica, anemia aplásica e anemia eritrocítica pura. em que A, X, Y~ 1~, Y~ 2~, Z, n, e R são descritos em detalhes na descrição.
BRPI0517416-3A 2004-10-12 2005-10-11 inibidores de pi3 quinase gama para o tratamento de anemia BRPI0517416A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104997 2004-10-12
PCT/EP2005/055156 WO2006040318A2 (en) 2004-10-12 2005-10-11 Pi3 kinase gamma inhibitors for the treatment of anaemia

Publications (1)

Publication Number Publication Date
BRPI0517416A true BRPI0517416A (pt) 2008-10-07

Family

ID=34929693

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517416-3A BRPI0517416A (pt) 2004-10-12 2005-10-11 inibidores de pi3 quinase gama para o tratamento de anemia

Country Status (14)

Country Link
US (1) US20090042773A1 (pt)
EP (1) EP1807075A2 (pt)
JP (1) JP2008515955A (pt)
KR (1) KR20070073857A (pt)
CN (1) CN101056633A (pt)
AU (1) AU2005293556A1 (pt)
BR (1) BRPI0517416A (pt)
CA (1) CA2580480A1 (pt)
EA (1) EA200700848A1 (pt)
IL (1) IL182110A0 (pt)
MX (1) MX2007004302A (pt)
NO (1) NO20072393L (pt)
WO (1) WO2006040318A2 (pt)
ZA (1) ZA200702435B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101052640B (zh) * 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途
EP2046333A4 (en) * 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
WO2010110380A1 (ja) * 2009-03-27 2010-09-30 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
US8633183B2 (en) * 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102584809B (zh) * 2011-01-14 2014-12-24 湘北威尔曼制药股份有限公司 胺基噻唑烷酮化合物及其制备方法与在制备抗肿瘤药物中的应用
EP2699569B1 (en) 2011-04-22 2017-08-30 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
KR101990605B1 (ko) 2011-11-04 2019-06-18 자스코 파머수티컬스, 엘엘씨 아미노피리미딘 키나아제 억제제
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos
JPWO2022163843A1 (pt) * 2021-02-01 2022-08-04

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
JP4782564B2 (ja) * 2002-07-10 2011-09-28 メルク セローノ ソシエテ アノニム アゾリジノン−ビニル縮合−ベンゼン誘導体
CN100579978C (zh) * 2002-11-22 2010-01-13 史密丝克莱恩比彻姆公司 化合物

Also Published As

Publication number Publication date
US20090042773A1 (en) 2009-02-12
CN101056633A (zh) 2007-10-17
WO2006040318A2 (en) 2006-04-20
KR20070073857A (ko) 2007-07-10
CA2580480A1 (en) 2006-04-20
ZA200702435B (en) 2008-06-25
EP1807075A2 (en) 2007-07-18
JP2008515955A (ja) 2008-05-15
IL182110A0 (en) 2007-07-24
NO20072393L (no) 2007-05-09
MX2007004302A (es) 2007-06-07
WO2006040318A3 (en) 2006-08-10
EA200700848A1 (ru) 2007-10-26
AU2005293556A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
BRPI0517416A (pt) inibidores de pi3 quinase gama para o tratamento de anemia
BRPI0415437A (pt) composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
BRPI0510409A (pt) heterociclos bicìclicos contendo nitrogênio como inibidores da aromatase
GEP20084367B (en) Diazepinoindole derivatives as kinase inhibitors
BR0312464A (pt) Inibidores de tirosina quinases
BR0208741A (pt) Derivados de piperidina
BRPI0413860A (pt) [1,8]naftiridin-2-onas e compostos relacionados para o tratamento de esquizofrenia
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
BRPI0613570B8 (pt) composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR0207726A (pt) Sais farmacêuticos
BRPI0508830B8 (pt) derivados de benzeno substituídos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0206588A (pt) Composto, processo para produzir o mesmo, uso do mesmo, composição farmacêutica, e, método para tratar um paciente afligido com uma condição patológica suscetìvel à melhora pelo antagonismo de integrinas alfa4beta1 e/ou alfa4beta7
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
UA84878C2 (ru) Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения
ATE407938T1 (de) Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
BR0112986A (pt) Compostos azabicìclicos, o respectivo preparo e a respectiva utilização como medicamentos, notadamente como antibacteriano
BRPI0607577A2 (pt) antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento
BRPI0411713B8 (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BRPI0510777A (pt) indazóis substituìdos, composições que os contêm, processo de produção e utilização
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.